{
    "hands_on_practices": [
        {
            "introduction": "The development of cancer in individuals with Hereditary Breast and Ovarian Cancer (HBOC) syndrome is often explained by the \"two-hit\" hypothesis for tumor suppressor genes. This model posits that a person inherits one non-functional allele (the \"first hit\") in every cell, and cancer initiates when a somatic event inactivates the remaining functional allele (the \"second hit\") in a single cell. This exercise provides a practical application of this core concept, challenging you to interpret realistic tumor sequencing data to confirm the complete loss of BRCA2 function, known as biallelic inactivation .",
            "id": "5044970",
            "problem": "A patient with Hereditary Breast and Ovarian Cancer syndrome is found to carry a germline frameshift variant in the gene BRCA2. A surgical tumor specimen from high-grade serous carcinoma undergoes next-generation sequencing and allele-specific copy-number analysis, which together demonstrate somatic copy-neutral loss of heterozygosity (LOH) at the BRCA2 locus. Tumor purity, defined as the fraction of nucleated cells in the specimen that are cancer cells, is estimated to be $p = 0.60$.\n\nUse the following foundational definitions:\n\n- Biallelic inactivation means both alleles of a tumor suppressor gene are functionally inactivated in the cancer cells.\n- Loss of heterozygosity (LOH) means the loss of one parental allele across a locus; copy-neutral LOH specifically means total copy number is unchanged, but one parental allele is lost and the other duplicated, eliminating heterozygosity.\n- A frameshift variant in a tumor suppressor gene is a loss-of-function event.\n\nBased solely on these definitions and the provided observations, first assess whether the tumor meets the criterion of biallelic inactivation of BRCA2. Then, assuming the LOH is clonal (present in all cancer cells in the specimen), compute the expected fraction $f$ of all cells in the specimen that are BRCA2-null in terms of tumor purity $p$, and evaluate $f$ at $p=0.60$. Express your final answer as a decimal fraction and round to three significant figures.",
            "solution": "The user wants me to first validate the problem statement and then, if it is valid, provide a solution.\n\n### Step 1: Extract Givens\n- Patient has Hereditary Breast and Ovarian Cancer syndrome with a germline frameshift variant in the gene BRCA2.\n- A tumor specimen from high-grade serous carcinoma shows somatic copy-neutral loss of heterozygosity (LOH) at the BRCA2 locus.\n- Tumor purity, $p$, is the fraction of nucleated cells in the specimen that are cancer cells.\n- The given tumor purity is $p = 0.60$.\n- Definition of biallelic inactivation: Both alleles of a tumor suppressor gene are functionally inactivated in the cancer cells.\n- Definition of copy-neutral LOH: Total copy number is unchanged, but one parental allele is lost and the other duplicated.\n- Definition of frameshift variant in a tumor suppressor gene: It is a loss-of-function event.\n- Assumption: The LOH is clonal, meaning it is present in all cancer cells in the specimen.\n- Task 1: Assess whether the tumor meets the criterion of biallelic inactivation of BRCA2.\n- Task 2: Compute the expected fraction $f$ of all cells in the specimen that are BRCA2-null in terms of tumor purity $p$.\n- Task 3: Evaluate $f$ for $p=0.60$.\n- Task 4: Express the final answer as a decimal fraction rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective. It describes a classic \"two-hit\" mechanism of tumorigenesis for a tumor suppressor gene, a cornerstone concept in cancer genetics first proposed by Knudson. The scenario is realistic: a germline mutation (first hit) is followed by a somatic event (second hit), in this case, LOH, leading to biallelic inactivation in the tumor. The provided definitions are standard and concise. The data ($p=0.60$) is a realistic value for tumor purity. The problem is self-contained, logically consistent, and has a unique, meaningful solution. There are no violations of the validation criteria.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. I will proceed with the solution.\n\n### Part 1: Assessment of Biallelic Inactivation\nThe patient carries a germline frameshift variant in BRCA2. A frameshift variant is defined as a loss-of-function event. This means that every cell in the patient's body, including the cell that gave rise to the tumor, began with one functional (wild-type) allele and one non-functional (mutant) BRCA2 allele. This germline mutation constitutes the \"first hit\" in the inactivation of this tumor suppressor gene.\n\nThe tumor cells are reported to have undergone somatic copy-neutral loss of heterozygosity (LOH) at the BRCA2 locus. LOH signifies the loss of one of the two parental alleles. In the context of a cell that is heterozygous for a functional and a non-functional allele, there is strong selective pressure for the loss of the remaining functional allele to promote oncogenesis. Therefore, the LOH event involves the loss of the wild-type BRCA2 allele. The term \"copy-neutral\" specifies that the lost allele is replaced by a duplication of the remaining allele. In this case, the non-functional frameshift allele is duplicated.\n\nAs a result of this somatic \"second hit\", the cancer cells no longer possess any functional BRCA2 alleles. Instead, they are homozygous for the loss-of-function frameshift variant, having two non-functional copies.\n\nThe problem defines biallelic inactivation as the state where \"both alleles of a tumor suppressor gene are functionally inactivated in the cancer cells.\" Since the cancer cells now possess two non-functional BRCA2 alleles, they precisely meet this criterion. Thus, the tumor demonstrates biallelic inactivation of BRCA2.\n\n### Part 2: Computation of the Fraction of BRCA2-Null Cells\nWe are asked to compute the expected fraction, $f$, of all cells in the specimen that are BRCA2-null. A cell is BRCA2-null if it has zero functional copies of the BRCA2 gene, which is equivalent to having biallelic inactivation.\n\nThe total population of nucleated cells in the specimen is a mixture of cancer cells and non-cancer cells (e.g., stromal cells, immune cells).\nLet $p$ be the tumor purity, representing the fraction of cells in the specimen that are cancer cells.\nThe fraction of non-cancer cells in the specimen is therefore $1-p$.\n\nWe must determine the BRCA2 status of each cell population:\n1.  **Cancer Cells:** As established in Part 1, the cancer cells have undergone clonal LOH, resulting in the loss of the functional allele and duplication of the non-functional allele. Therefore, all cancer cells are BRCA2-null. The fraction of all cells in the sample that are both cancer cells and BRCA2-null is $p \\times 1 = p$.\n2.  **Non-Cancer Cells:** These cells are part of the patient's normal tissue and have not undergone the somatic LOH event. They retain the patient's germline genotype, which is heterozygous for BRCA2 (one functional allele, one non-functional allele). As they possess one functional allele, they are not BRCA2-null. The fraction of all cells in the sample that are both non-cancer cells and BRCA2-null is $(1-p) \\times 0 = 0$.\n\nThe total fraction $f$ of BRCA2-null cells in the specimen is the sum of the fractions from these two populations:\n$$f = (\\text{fraction of cancer cells that are BRCA2-null}) + (\\text{fraction of normal cells that are BRCA2-null})$$\n$$f = p + 0$$\n$$f = p$$\nThus, the expected fraction of all cells in the specimen that are BRCA2-null is equal to the tumor purity, $p$.\n\n### Part 3: Numerical Evaluation\nThe problem provides the tumor purity as $p = 0.60$.\nSubstituting this value into our derived expression:\n$$f = 0.60$$\nThe problem requires the answer to be expressed as a decimal fraction rounded to three significant figures. The number $0.60$ has two significant figures. To express this value with three significant figures, we write it as $0.600$.\n$$f = 0.600$$",
            "answer": "$$\\boxed{0.600}$$"
        },
        {
            "introduction": "In medical genetics, assessing a patient's risk is often a process of updating probabilities as new information becomes available, a perfect scenario for applying Bayes' theorem. This practice problem simulates a common genetic counseling scenario where an individual's initial risk of carrying a mutation, based on Mendelian inheritance, must be adjusted based on their own health status. By calculating the posterior probability that a woman is a BRCA2 carrier given that she is currently unaffected, you will gain hands-on experience in how personal data refines inherited genetic risk .",
            "id": "5044937",
            "problem": "A $40$-year-old woman with no personal history of breast or ovarian cancer seeks risk assessment. Her mother was diagnosed with breast cancer at age $45$ and has tested positive for a known pathogenic variant in BReast CAncer gene $2$ (BRCA2). Her maternal aunt (the mother’s sister) is unaffected at age $70$. Assume autosomal dominant inheritance with Mendelian segregation and the following penetrance information for female BRCA2 pathogenic variant carriers and for non-carriers, expressed as cumulative risks by a given age for developing at least one of breast or ovarian cancer:\n- By age $40$: carriers have risk $0.19$; non-carriers have risk $0.016$.\n- By age $70$: carriers have risk $0.62$; non-carriers have risk $0.09$.\nAssume the mother’s genetic test has perfect analytic validity (sensitivity and specificity equal to $1$), so her carrier status is known with certainty. The proband is unaffected at age $40$.\n\nUsing only fundamental principles of Mendelian inheritance, the definition of penetrance, and Bayes’ theorem, compute the posterior probability that the unaffected $40$-year-old proband carries her mother’s familial BRCA2 pathogenic variant. Express your final answer as a decimal rounded to four significant figures.",
            "solution": "The problem statement is scientifically grounded, self-contained, consistent, and well-posed. It describes a classic scenario in genetic risk assessment that can be solved using fundamental principles of Mendelian genetics and Bayesian probability theory. The provided data are realistic and sufficient for a unique solution. Therefore, the problem is valid.\n\nThe objective is to calculate the posterior probability that a $40$-year-old woman (the proband), who is currently unaffected by breast or ovarian cancer, is a carrier of a familial pathogenic variant in the BReast CAncer gene $2$ (BRCA2).\n\nLet's define the relevant hypotheses and evidence:\n$H_C$: The hypothesis that the proband is a carrier of the BRCA2 pathogenic variant.\n$H_{NC}$: The hypothesis that the proband is not a carrier of the BRCA2 pathogenic variant.\n$E$: The evidence that the proband is unaffected by breast or ovarian cancer at her current age of $40$.\n\nWe need to compute the posterior probability $P(H_C|E)$, which is the probability of the proband being a carrier given that she is unaffected at age $40$. We will use Bayes' theorem for this calculation.\n\nFirst, we establish the prior probabilities of the hypotheses, $P(H_C)$ and $P(H_{NC})$. The proband's mother is a known carrier of a BRCA2 pathogenic variant. Since BRCA2-associated cancer risk is inherited in an autosomal dominant fashion, there is a $50\\%$ chance for a child to inherit the variant from an affected parent. This is based on Mendelian segregation.\nTherefore, the prior probability that the proband is a carrier is:\n$$ P(H_C) = 0.5 $$\nThe prior probability that she is not a carrier is complementary:\n$$ P(H_{NC}) = 1 - P(H_C) = 1 - 0.5 = 0.5 $$\n\nNext, we determine the conditional probabilities of the evidence given each hypothesis. These are also known as the likelihoods, $P(E|H_C)$ and $P(E|H_{NC})$. The problem provides penetrance data, which is the cumulative risk of developing cancer by a certain age.\nLet $A_{40}$ be the event that a woman develops breast or ovarian cancer by age $40$. The problem gives:\nThe risk for a carrier by age $40$: $P(A_{40}|H_C) = 0.19$.\nThe risk for a non-carrier by age $40$: $P(A_{40}|H_{NC}) = 0.016$.\n\nThe evidence $E$ is that the proband is *unaffected*, which is the complement of the event $A_{40}$. Thus, the likelihoods are:\nThe probability of a carrier being unaffected at age $40$:\n$$ P(E|H_C) = P(\\text{not } A_{40}|H_C) = 1 - P(A_{40}|H_C) = 1 - 0.19 = 0.81 $$\nThe probability of a non-carrier being unaffected at age $40$:\n$$ P(E|H_{NC}) = P(\\text{not } A_{40}|H_{NC}) = 1 - P(A_{40}|H_{NC}) = 1 - 0.016 = 0.984 $$\n\nNow, we can apply Bayes' theorem to find the posterior probability $P(H_C|E)$:\n$$ P(H_C|E) = \\frac{P(E|H_C) P(H_C)}{P(E)} $$\nThe denominator, $P(E)$, is the total probability of the evidence, which is calculated using the law of total probability:\n$$ P(E) = P(E|H_C) P(H_C) + P(E|H_{NC}) P(H_{NC}) $$\n\nSubstituting the numerical values into the expression for $P(E)$:\n$$ P(E) = (0.81)(0.5) + (0.984)(0.5) $$\n$$ P(E) = 0.405 + 0.492 = 0.897 $$\n\nNow, substitute this back into the Bayes' theorem formula for the posterior probability:\n$$ P(H_C|E) = \\frac{(0.81)(0.5)}{0.897} = \\frac{0.405}{0.897} $$\n\nCalculating the final value:\n$$ P(H_C|E) \\approx 0.4515050167... $$\n\nThe problem requires the final answer to be expressed as a decimal rounded to four significant figures.\n$$ P(H_C|E) \\approx 0.4515 $$\nThe information about the maternal aunt and the penetrance data for age $70$ are not required for this specific calculation, which focuses on the proband's current risk at age $40$ given her mother's confirmed carrier status. The proband's prior risk is entirely determined by her mother's genotype due to Mendelian inheritance, and her posterior risk is an update of this prior risk based on her own current health status.",
            "answer": "$$\\boxed{0.4515}$$"
        },
        {
            "introduction": "While genetic testing is a powerful tool, no test is perfect, and its results must be interpreted in the context of the patient's prior risk. This is especially true when a person with a strong family history receives a negative result. This exercise guides you through the calculation of post-test probability, demonstrating how to use a test's analytical sensitivity to determine the \"residual risk\" that remains, a critical concept for accurate genetic counseling and patient management .",
            "id": "5044956",
            "problem": "A 32-year-old woman with multiple affected relatives consistent with Hereditary Breast and Ovarian Cancer due to BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) undergoes a Next-Generation Sequencing (NGS) multigene panel that interrogates the coding exons and canonical splice sites of BRCA1, includes copy-number analysis for large rearrangements, and is reported as negative for pathogenic or likely pathogenic variants. Independent of the test, a validated familial risk model estimates her prior probability of carrying a pathogenic BRCA1 variant as $P(\\text{carrier}) = 0.32$. The analytical sensitivity of the panel for pathogenic BRCA1 variants is $0.97$, and the analytical specificity is $0.995$. Use the core definitions that sensitivity is $P(\\text{positive} \\mid \\text{carrier})$ and specificity is $P(\\text{negative} \\mid \\text{non-carrier})$, and compute the post-test probability $P(\\text{carrier} \\mid \\text{negative})$.\n\nExpress your final answer as a decimal and round to four significant figures.",
            "solution": "The problem statement is evaluated as valid. It is scientifically grounded in the principles of medical genetics and Bayesian statistics, is well-posed with all necessary information provided, and is expressed in objective, precise language. There are no contradictions, ambiguities, or violations of scientific principles. We may therefore proceed with the solution.\n\nThe objective is to calculate the post-test probability of a woman being a carrier of a pathogenic BRCA1 variant, given that her genetic test result was negative. This is a conditional probability, which can be determined using Bayes' theorem.\n\nLet $C$ be the event that the woman is a carrier of a pathogenic BRCA1 variant.\nLet $\\neg C$ be the event that the woman is not a carrier.\nLet `pos` be the event that the test result is positive.\nLet `neg` be the event that the test result is negative.\n\nWe are asked to find $P(C \\mid \\text{neg})$.\n\nFrom the problem statement, we are given the following probabilities:\n1.  The prior probability of being a carrier, based on a familial risk model:\n    $$ P(C) = 0.32 $$\n2.  The analytical sensitivity of the test, defined as the probability of a positive test result given the individual is a carrier:\n    $$ \\text{Sensitivity} = P(\\text{pos} \\mid C) = 0.97 $$\n3.  The analytical specificity of the test, defined as the probability of a negative test result given the individual is not a carrier:\n    $$ \\text{Specificity} = P(\\text{neg} \\mid \\neg C) = 0.995 $$\n\nFirst, we derive the probabilities needed for Bayes' theorem.\nThe probability of not being a carrier is the complement of being a carrier:\n$$ P(\\neg C) = 1 - P(C) = 1 - 0.32 = 0.68 $$\nThe probability of a negative test result given that the woman is a carrier (the false negative rate) is the complement of the sensitivity:\n$$ P(\\text{neg} \\mid C) = 1 - P(\\text{pos} \\mid C) = 1 - 0.97 = 0.03 $$\n\nBayes' theorem for the posterior probability $P(C \\mid \\text{neg})$ is:\n$$ P(C \\mid \\text{neg}) = \\frac{P(\\text{neg} \\mid C) P(C)}{P(\\text{neg})} $$\n\nThe denominator, $P(\\text{neg})$, is the total probability of obtaining a negative test result. It can be calculated using the law of total probability:\n$$ P(\\text{neg}) = P(\\text{neg} \\mid C) P(C) + P(\\text{neg} \\mid \\neg C) P(\\neg C) $$\n\nNow, we substitute the known values into this equation:\n$$ P(\\text{neg}) = (0.03)(0.32) + (0.995)(0.68) $$\nCalculating each term:\n$$ (0.03)(0.32) = 0.0096 $$\n$$ (0.995)(0.68) = 0.6766 $$\nSumming these gives the total probability of a negative result:\n$$ P(\\text{neg}) = 0.0096 + 0.6766 = 0.6862 $$\n\nNow we can substitute the values for the numerator and the denominator back into Bayes' theorem:\n$$ P(C \\mid \\text{neg}) = \\frac{P(\\text{neg} \\mid C) P(C)}{P(\\text{neg})} = \\frac{0.0096}{0.6862} $$\n\nPerforming the final calculation:\n$$ P(C \\mid \\text{neg}) \\approx 0.013989799... $$\n\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $1$, $3$, $9$, and $8$. The fifth significant figure is $9$, which is greater than or equal to $5$, so we round up the fourth significant figure.\n$$ P(C \\mid \\text{neg}) \\approx 0.01399 $$\n\nThus, the post-test probability of the woman carrying a pathogenic BRCA1 variant despite a negative test result is approximately $0.01399$, or about $1.4\\%$.",
            "answer": "$$\\boxed{0.01399}$$"
        }
    ]
}